	US 12,280,103 B2
	Coronavirus vaccine compositions, methods, and uses thereof
Peng Liang, Chengdu Sichuan (CN); and Joshua Liang, Chengdu Sichuan (CN)
Assigned to Sichuan Clover Biopharmaceuticals, Inc., Chengdu (CN)
Filed by Sichuan Clover Biopharmaceuticals, Inc., Sichuan (CN)
Filed on Jun. 5, 2022, as Appl. No. 17/832,664.
Application 17/832,664 is a continuation of application No. 17/489,572, filed on Sep. 29, 2021, granted, now 11,389,528.
Application 17/489,572 is a continuation of application No. PCT/CN2021/099285, filed on Jun. 10, 2021.
Claims priority of application No. PCT/CN2020/095269 (WO), filed on Jun. 10, 2020; application No. PCT/CN2021/087066 (WO), filed on Apr. 13, 2021; and application No. PCT/CN2021/093895 (WO), filed on May 14, 2021.
Prior Publication US 2023/0096093 A1, Mar. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/215 (2006.01); A61K 39/00 (2006.01); A61P 31/14 (2006.01); A61P 37/04 (2006.01); C07K 14/005 (2006.01); C07K 14/78 (2006.01)

CPC A61K 39/215 (2013.01) [A61P 37/04 (2018.01); C07K 14/005 (2013.01); C07K 14/78 (2013.01); A61K 2039/54 (2013.01); A61K 2039/543 (2013.01); A61K 2039/545 (2013.01); C07K 2319/00 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01); C12N 2770/20071 (2013.01)]

20 Claims

1. An immunogenic composition comprising:

a) a fusion polypeptide comprising a SARS-CoV-2 spike (S) ectodomain polypeptide and a C-propeptide of a human pro-collagen, wherein the C-propeptide is configured to form a disulfide bond-linked homotrimer; and

b) one or more adjuvants.